{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:49:17Z","timestamp":1770176957460,"version":"3.49.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["NSTC110-2320-B-038-016-MY3"],"award-info":[{"award-number":["NSTC110-2320-B-038-016-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Education in Taiwan","award":["DP2-TMU-113-N-01"],"award-info":[{"award-number":["DP2-TMU-113-N-01"]}]},{"name":"Ministry of Education in Taiwan","award":["DP2-TMU-114-N-01"],"award-info":[{"award-number":["DP2-TMU-114-N-01"]}]},{"DOI":"10.13039\/501100016004","name":"Institute of Biomedical Sciences, Academia Sinica","doi-asserted-by":"publisher","award":["AS-KPQ-111-KNT"],"award-info":[{"award-number":["AS-KPQ-111-KNT"]}],"id":[{"id":"10.13039\/501100016004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder with epileptic seizures caused by genetic mutations in either TSC1 or TSC2 gene. Multiple genetic, epigenetic, and environmental factors can affect the phenotypical outcomes of TSC individuals. Accumulating evidence has shown that the seizures occurred in early life may contribute to the epileptogenesis and aggravate the neurological setting and neuropsychiatric symptoms of TSC. Therefore, treatments targeting seizures and\/or epileptogenesis have always been the main focus on TSC therapies. Current anti-epileptic drugs and mTOR inhibitors show some efficacy, yet up to one-third of TSC-epileptic individuals are classified as refractory epilepsy. Vigabatrin, which has been used as the first-line therapy for infantile spasms in TSC, has demonstrated to delay the onset and lower the overall incidence of seizures in infants with TSC when it was used as a preventive treatment. Recently, because of its efficacy, cannabidiol, which targets adenosine signaling pathway, has been approved by the U.S. FDA for the treatment of TSC-associated epilepsy, suggesting an anti-epilepsy strategy other than mTOR inhibition is also plausible for TSC. To this end, we sought for a preventative treatment of an adenosine pathway-targeted therapeutic strategy. In this study, we pretreated\n                    <jats:italic>Tsc2<\/jats:italic>\n                    <jats:sup>+\/\u2013<\/jats:sup>\n                    mice with J4, an equilibrative nucleoside transporter 1 inhibitor, before the initiation of kindling epileptogenesis driven by the repetitive PTZ induction paradigm. We found that J4 reduced the seizure behavior severity in\n                    <jats:italic>Tsc2<\/jats:italic>\n                    <jats:sup>+\/\u2013<\/jats:sup>\n                    mice, as well as decreased mossy fiber sprouting resulted from the aberrant neurogenesis upon PTZ injurious insults. We also found that J4 increased the expression of GluR2, inhibited the astrogliosis and microgliosis, and eventually prevented the neuronal cell loss due to the excitotoxicity. The present study provides a new alternative therapeutic concept for pretreating TSC-related epilepsy before the epileptogenesis process.\n                  <\/jats:p>","DOI":"10.1186\/s13578-025-01518-3","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T01:53:11Z","timestamp":1767491591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-seizure potential of J4, an equilibrative nucleoside transporter 1 inhibitor, in a mouse model of tuberous sclerosis complex in response to pentylenetetrazol"],"prefix":"10.1186","volume":"16","author":[{"given":"Christine Chin-jung","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Kuei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Yu","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Xuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thu Thi Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijuang","family":"Chern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-183X","authenticated-orcid":false,"given":"Yi-Chao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"1","key":"1518_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/epi4.12286","volume":"4","author":"R Nabbout","year":"2019","unstructured":"Nabbout R, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA study. Epilepsia Open. 2019;4(1):73\u201384.","journal-title":"Epilepsia Open"},{"key":"1518_CR2","doi-asserted-by":"publisher","first-page":"175628642110311","DOI":"10.1177\/17562864211031100","volume":"14","author":"S Schubert-Bast","year":"2021","unstructured":"Schubert-Bast S, Strzelczyk A. Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Ther Adv Neurol Disord. 2021;14:17562864211031100.","journal-title":"Ther Adv Neurol Disord"},{"key":"1518_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/NDT.S347327","volume":"19","author":"A Singh","year":"2023","unstructured":"Singh A, et al. Treatment-Resistant epilepsy and tuberous sclerosis complex: Treatment, Maintenance, and future directions. Neuropsychiatr Dis Treat. 2023;19:733\u201348.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"1518_CR4","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","volume":"51","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236\u201341.","journal-title":"Epilepsia"},{"issue":"10056","key":"1518_CR5","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/TCRM.S145630","volume":"15","author":"IE Overwater","year":"2019","unstructured":"Overwater IE, et al. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. Ther Clin Risk Manag. 2019;15:951\u20135.","journal-title":"Ther Clin Risk Manag"},{"issue":"21","key":"1518_CR7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med"},{"issue":"20","key":"1518_CR8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, et al. Effect of Cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888\u201397.","journal-title":"N Engl J Med"},{"issue":"2","key":"1518_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/epi.17150","volume":"63","author":"EA Thiele","year":"2022","unstructured":"Thiele EA, et al. Long-term Cannabidiol treatment for seizures in patients with tuberous sclerosis complex: an open-label extension trial. Epilepsia. 2022;63(2):426\u201339.","journal-title":"Epilepsia"},{"issue":"S1","key":"1518_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1684\/epd.2020.1135","volume":"22","author":"RA Gray","year":"2020","unstructured":"Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10\u20135.","journal-title":"Epileptic Disord"},{"issue":"6","key":"1518_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791\u2013802.","journal-title":"Epilepsia"},{"issue":"20","key":"1518_CR12","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.0511232103","volume":"103","author":"EJ Carrier","year":"2006","unstructured":"Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci. 2006;103(20):7895\u2013900.","journal-title":"Proc Natl Acad Sci"},{"key":"1518_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/B978-0-12-801022-8.00011-8","volume":"119","author":"SA Masino","year":"2014","unstructured":"Masino SA, Kawamura M Jr., Ruskin DN. Adenosine receptors and epilepsy: current evidence and future potential. Int Rev Neurobiol. 2014;119:233\u201355.","journal-title":"Int Rev Neurobiol"},{"key":"1518_CR14","doi-asserted-by":"publisher","first-page":"107741","DOI":"10.1016\/j.neuropharm.2019.107741","volume":"167","author":"D Boison","year":"2020","unstructured":"Boison D, Rho JM. Epigenetics and epilepsy prevention: the therapeutic potential of adenosine and metabolic therapies. Neuropharmacology. 2020;167:107741.","journal-title":"Neuropharmacology"},{"issue":"14","key":"1518_CR15","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1111\/bph.16094","volume":"181","author":"J-A Baltos","year":"2024","unstructured":"Baltos J-A, et al. The role of the adenosine system in epilepsy and its comorbidities. Br J Pharmacol. 2024;181(14):2143\u201357.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1518_CR16","first-page":"571","volume":"118","author":"T Li","year":"2008","unstructured":"Li T, et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest. 2008;118(2):571\u201382.","journal-title":"J Clin Invest"},{"key":"1518_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nbd.2018.10.005","volume":"121","author":"H Luna-Munguia","year":"2019","unstructured":"Luna-Munguia H, et al. Chemical biomarkers of epileptogenesis and ictogenesis in experimental epilepsy. Neurobiol Dis. 2019;121:177\u201386.","journal-title":"Neurobiol Dis"},{"issue":"9","key":"1518_CR18","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/j.1528-1167.2011.03115.x","volume":"52","author":"E Aronica","year":"2011","unstructured":"Aronica E, et al. Upregulation of adenosine kinase in astrocytes in experimental and human Temporal lobe epilepsy. Epilepsia. 2011;52(9):1645\u201355.","journal-title":"Epilepsia"},{"issue":"8","key":"1518_CR19","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1172\/JCI65636","volume":"123","author":"RL Williams-Karnesky","year":"2013","unstructured":"Williams-Karnesky RL, et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest. 2013;123(8):3552\u201363.","journal-title":"J Clin Invest"},{"issue":"Pt 5","key":"1518_CR20","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/brain\/awm057","volume":"130","author":"T Li","year":"2007","unstructured":"Li T, et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain. 2007;130(Pt 5):1276\u201388.","journal-title":"Brain"},{"issue":"4","key":"1518_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/epi.14674","volume":"60","author":"US Sandau","year":"2019","unstructured":"Sandau US, et al. Transient use of a systemic adenosine kinase inhibitor attenuates epilepsy development in mice. Epilepsia. 2019;60(4):615\u201325.","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"1518_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0014-2999(97)01451-9","volume":"340","author":"AF Ambr\u00f3sio","year":"1997","unstructured":"Ambr\u00f3sio AF, et al. Inhibition of N-,P\/Q- and other types of Ca2\u2009+\u2009channels in rat hippocampal nerve terminals by the adenosine A1 receptor. Eur J Pharmacol. 1997;340(2\u20133):301\u201310.","journal-title":"Eur J Pharmacol"},{"key":"1518_CR23","doi-asserted-by":"crossref","unstructured":"Dunwiddie TV, Masino SA. The Role and Regulation of Adenosine in the Central Nervous System. Annual Rev Neurosci. 2001; 24: 31\u201355.","DOI":"10.1146\/annurev.neuro.24.1.31"},{"issue":"1","key":"1518_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1113\/jphysiol.1992.sp019168","volume":"451","author":"SM Thompson","year":"1992","unstructured":"Thompson SM, Haas HL, G\u00e4hwiler BH. Comparison of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus in vitro. J Physiol. 1992;451(1):347\u201363.","journal-title":"J Physiol"},{"key":"1518_CR25","doi-asserted-by":"publisher","first-page":"109600","DOI":"10.1016\/j.neuropharm.2023.109600","volume":"236","author":"AM Sebasti\u00e3o","year":"2023","unstructured":"Sebasti\u00e3o AM, Ribeiro JA. Adjusting the brakes to adjust neuronal activity: adenosinergic modulation of GABAergic transmission. Neuropharmacology. 2023;236:109600.","journal-title":"Neuropharmacology"},{"key":"1518_CR26","doi-asserted-by":"publisher","first-page":"114321","DOI":"10.1016\/j.bcp.2020.114321","volume":"187","author":"D Boison","year":"2021","unstructured":"Boison D, Jarvis MF. Adenosine kinase: A key regulator of purinergic physiology. Biochem Pharmacol. 2021;187:114321.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1518_CR27","doi-asserted-by":"publisher","first-page":"e00506","DOI":"10.1002\/prp2.506","volume":"7","author":"MF Jarvis","year":"2019","unstructured":"Jarvis MF. Therapeutic potential of adenosine kinase inhibition\u2014Revisited. Pharmacol Res Perspect. 2019;7(4):e00506.","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"1518_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","volume":"447","author":"SA Baldwin","year":"2004","unstructured":"Baldwin SA, et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;447(5):735\u201343.","journal-title":"Pflugers Arch"},{"key":"1518_CR29","doi-asserted-by":"crossref","unstructured":"Chen J-F, Lee C-f, Chern Y. Chapter One - Adenosine Receptor Neurobiology: Overview, in International Review of Neurobiology, A. Mori, Editor. 2014, Academic Press. pp. 1\u201349.","DOI":"10.1016\/B978-0-12-801022-8.00001-5"},{"issue":"8","key":"1518_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.tips.2006.06.004","volume":"27","author":"AE King","year":"2006","unstructured":"King AE, et al. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci. 2006;27(8):416\u201325.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1518_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-014-8338-2","volume":"17","author":"Z Xu","year":"2015","unstructured":"Xu Z, et al. ENT1 Inhibition attenuates epileptic seizure severity via regulation of glutamatergic neurotransmission. Neuromolecular Med. 2015;17(1):1\u201311.","journal-title":"Neuromolecular Med"},{"issue":"3","key":"1518_CR32","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","volume":"98","author":"PA Borea","year":"2018","unstructured":"Borea PA, et al. Pharmacology of adenosine receptors: the state of the Art. Physiol Rev. 2018;98(3):1591\u2013625.","journal-title":"Physiol Rev"},{"key":"1518_CR33","doi-asserted-by":"publisher","first-page":"109954","DOI":"10.1016\/j.cellsig.2021.109954","volume":"82","author":"SM McNeill","year":"2021","unstructured":"McNeill SM, et al. Biased agonism at adenosine receptors. Cell Signal. 2021;82:109954.","journal-title":"Cell Signal"},{"issue":"21","key":"1518_CR34","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1111\/bph.14337","volume":"175","author":"EA Vecchio","year":"2018","unstructured":"Vecchio EA, et al. New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. Br J Pharmacol. 2018;175(21):4036\u201346.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1518_CR35","doi-asserted-by":"publisher","first-page":"e20934","DOI":"10.1371\/journal.pone.0020934","volume":"6","author":"NK Huang","year":"2011","unstructured":"Huang NK, et al. A new drug design targeting the adenosinergic system for huntington\u2019s disease. PLoS ONE. 2011;6(6):e20934.","journal-title":"PLoS ONE"},{"issue":"12","key":"1518_CR36","doi-asserted-by":"publisher","first-page":"8936","DOI":"10.1007\/s12035-018-1030-z","volume":"55","author":"CC Lee","year":"2018","unstructured":"Lee CC, et al. Adenosine augmentation evoked by an ENT1 inhibitor improves memory impairment and neuronal plasticity in the APP\/PS1 mouse model of alzheimer\u2019s disease. Mol Neurobiol. 2018;55(12):8936\u201352.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1518_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40478-021-01213-7","volume":"9","author":"CP Chang","year":"2021","unstructured":"Chang CP, et al. Equilibrative nucleoside transporter 1 Inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathol Commun. 2021;9(1):112.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1518_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12929-021-00766-y","volume":"28","author":"CP Chang","year":"2021","unstructured":"Chang CP, et al. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. J Biomed Sci. 2021;28(1):70.","journal-title":"J Biomed Sci"},{"issue":"1","key":"1518_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12035-022-03080-2","volume":"60","author":"KY Chen","year":"2023","unstructured":"Chen KY, et al. Equilibrative nucleoside transporter 1 is a target to modulate neuroinflammation and improve functional recovery in mice with spinal cord injury. Mol Neurobiol. 2023;60(1):369\u201381.","journal-title":"Mol Neurobiol"},{"key":"1518_CR40","doi-asserted-by":"publisher","first-page":"610898","DOI":"10.3389\/fnins.2020.610898","volume":"14","author":"SY Ho","year":"2020","unstructured":"Ho SY, et al. Equilibrative nucleoside Transporters-1 inhibitors act as Anti-epileptic agents by inhibiting glutamatergic transmission. Front Neurosci. 2020;14:610898.","journal-title":"Front Neurosci"},{"issue":"3","key":"1518_CR41","first-page":"e80387","volume":"17","author":"H Kolomar","year":"2025","unstructured":"Kolomar H, et al. A comprehensive review on the influence of menstrual cycle and pregnancy on epileptic seizures. Cureus. 2025;17(3):e80387.","journal-title":"Cureus"},{"key":"1518_CR42","doi-asserted-by":"crossref","unstructured":"Shimada T, Yamagata K. Pentylenetetrazole-Induced kindling mouse model. J Vis Exp. 2018;136: e56573.","DOI":"10.3791\/56573-v"},{"issue":"8","key":"1518_CR43","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/jn\/132.8.2288","volume":"132","author":"MG Tordoff","year":"2002","unstructured":"Tordoff MG, et al. The maintenance diets of C57BL\/6J and 129X1\/SvJ mice influence their taste solution preferences: implications for large-scale phenotyping projects. J Nutr. 2002;132(8):2288\u201397.","journal-title":"J Nutr"},{"issue":"1","key":"1518_CR44","doi-asserted-by":"publisher","first-page":"13211","DOI":"10.1038\/s41598-017-13581-z","volume":"7","author":"H Morrison","year":"2017","unstructured":"Morrison H, et al. Quantitative microglia analyses reveal diverse morphologic responses in the rat cortex after diffuse brain injury. Sci Rep. 2017;7(1):13211.","journal-title":"Sci Rep"},{"issue":"1","key":"1518_CR45","doi-asserted-by":"publisher","first-page":"18196","DOI":"10.1038\/s41598-022-23091-2","volume":"12","author":"TRF Green","year":"2022","unstructured":"Green TRF, Murphy SM, Rowe RK. Comparisons of quantitative approaches for assessing microglial morphology reveal inconsistencies, ecological fallacy, and a need for standardization. Sci Rep. 2022;12(1):18196.","journal-title":"Sci Rep"},{"issue":"6","key":"1518_CR46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda H, et al. Tsc2(+\/-) mice develop tumors in multiple sites that express Gelsolin and are influenced by genetic background. J Clin Invest. 1999;104(6):687\u201395.","journal-title":"J Clin Invest"},{"issue":"8","key":"1518_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1788","volume":"14","author":"D Ehninger","year":"2008","unstructured":"Ehninger D, et al. Reversal of learning deficits in a Tsc2+\/- mouse model of tuberous sclerosis. Nat Med. 2008;14(8):843\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"1518_CR48","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1471-4159.2005.03538.x","volume":"96","author":"R Waltereit","year":"2006","unstructured":"Waltereit R, et al. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J Neurochem. 2006;96(2):407\u201313.","journal-title":"J Neurochem"},{"issue":"24","key":"1518_CR49","doi-asserted-by":"publisher","first-page":"8862","DOI":"10.1523\/JNEUROSCI.1617-11.2011","volume":"31","author":"HS Bateup","year":"2011","unstructured":"Bateup HS, et al. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci. 2011;31(24):8862\u20139.","journal-title":"J Neurosci"},{"issue":"12","key":"1518_CR50","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/nn1566","volume":"8","author":"SF Tavazoie","year":"2005","unstructured":"Tavazoie SF, et al. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci. 2005;8(12):1727\u201334.","journal-title":"Nat Neurosci"},{"issue":"2","key":"1518_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.21058","volume":"61","author":"Y Wang","year":"2007","unstructured":"Wang Y, et al. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol. 2007;61(2):139\u201352.","journal-title":"Ann Neurol"},{"issue":"3","key":"1518_CR52","doi-asserted-by":"publisher","first-page":"111085","DOI":"10.1016\/j.celrep.2022.111085","volume":"40","author":"X Wu","year":"2022","unstructured":"Wu X, et al. Synaptic hyperexcitability of cytomegalic pyramidal neurons contributes to epileptogenesis in tuberous sclerosis complex. Cell Rep. 2022;40(3):111085.","journal-title":"Cell Rep"},{"key":"1518_CR53","doi-asserted-by":"publisher","unstructured":"Bassetti D, Luhmann HJ. Kirischuk Effects of mutations in TSC genes on neurodevelopment and synaptic transmission. Int J Mol Sci. 2021 https:\/\/doi.org\/10.3390\/ijms22147273.","DOI":"10.3390\/ijms22147273"},{"issue":"1","key":"1518_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13041-019-0427-6","volume":"12","author":"JP Zhao","year":"2019","unstructured":"Zhao JP, Yoshii A. Hyperexcitability of the local cortical circuit in mouse models of tuberous sclerosis complex. Mol Brain. 2019;12(1):6.","journal-title":"Mol Brain"},{"issue":"6","key":"1518_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.neuron.2007.06.001","volume":"54","author":"JTR Isaac","year":"2007","unstructured":"Isaac JTR, Ashby MC, McBain CJ. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron. 2007;54(6):859\u201371.","journal-title":"Neuron"},{"issue":"Suppl 2","key":"1518_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1528-1167.2007.01071.x","volume":"48","author":"JR Naegele","year":"2007","unstructured":"Naegele JR. Neuroprotective strategies to avert seizure-induced neurodegeneration in epilepsy. Epilepsia. 2007;48(Suppl 2):107\u201317.","journal-title":"Epilepsia"},{"issue":"1","key":"1518_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5115\/acb.19.083","volume":"53","author":"HK Mohamed","year":"2020","unstructured":"Mohamed HK, Eltony SA. Effect of acute Pentylenetetrazol injection induced epileptic seizures on rat dentate gyrus at different postnatal ages. Anat Cell Biol. 2020;53(1):84\u201394.","journal-title":"Anat Cell Biol"},{"issue":"2","key":"1518_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.neuroscience.2006.02.076","volume":"140","author":"JH Park","year":"2006","unstructured":"Park JH, et al. Repeated brief epileptic seizures by Pentylenetetrazole cause neurodegeneration and promote neurogenesis in discrete brain regions of freely moving adult rats. Neuroscience. 2006;140(2):673\u201384.","journal-title":"Neuroscience"},{"issue":"1","key":"1518_CR59","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0896-6273(95)90076-4","volume":"15","author":"JR Geiger","year":"1995","unstructured":"Geiger JR, et al. Relative abundance of subunit mRNAs determines gating and Ca2\u2009+\u2009permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron. 1995;15(1):193\u2013204.","journal-title":"Neuron"},{"issue":"6","key":"1518_CR60","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/nn1472","volume":"8","author":"D Davalos","year":"2005","unstructured":"Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8(6):752\u20138.","journal-title":"Nat Neurosci"},{"issue":"3","key":"1518_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","volume":"36","author":"O Devinsky","year":"2013","unstructured":"Devinsky O, et al. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013;36(3):174\u201384.","journal-title":"Trends Neurosci"},{"issue":"3","key":"1518_CR62","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.neuron.2013.03.017","volume":"78","author":"HS Bateup","year":"2013","unstructured":"Bateup HS, et al. Excitatory\/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron. 2013;78(3):510\u201322.","journal-title":"Neuron"},{"issue":"1","key":"1518_CR63","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1038\/s41467-019-12962-4","volume":"10","author":"R Malik","year":"2019","unstructured":"Malik R, et al. Tsc1 represses parvalbumin expression and fast-spiking properties in somatostatin lineage cortical interneurons. Nat Commun. 2019;10(1):4994.","journal-title":"Nat Commun"},{"key":"1518_CR64","doi-asserted-by":"publisher","first-page":"968115","DOI":"10.3389\/fnins.2022.968115","volume":"16","author":"S Pietropaolo","year":"2022","unstructured":"Pietropaolo S, Provenzano G. Editorial: targeting Excitation-Inhibition imbalance in neurodevelopmental and autism spectrum disorders. Front Neurosci. 2022;16:968115.","journal-title":"Front Neurosci"},{"issue":"7","key":"1518_CR65","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrneurol.2009.80","volume":"5","author":"SN Rakhade","year":"2009","unstructured":"Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol. 2009;5(7):380\u201391.","journal-title":"Nat Rev Neurol"},{"key":"1518_CR66","doi-asserted-by":"crossref","unstructured":"Pracucci E et al. Neuroinflammation: A signature or a cause of epilepsy?. Int J Mol Sci. 2021;22(13): 6981.","DOI":"10.3390\/ijms22136981"},{"key":"1518_CR67","doi-asserted-by":"crossref","unstructured":"Suleymanova EM. Behavioral comorbidities of epilepsy and neuroinflammation: evidence from experimental and clinical studies. Epilepsy & Behavior; 2021. p. 117.","DOI":"10.1016\/j.yebeh.2021.107869"},{"key":"1518_CR68","doi-asserted-by":"publisher","first-page":"103288","DOI":"10.1016\/j.nicl.2022.103288","volume":"37","author":"K Kagitani-Shimono","year":"2023","unstructured":"Kagitani-Shimono K, et al. Extension of microglial activation is associated with epilepsy and cognitive dysfunction in tuberous sclerosis complex: A TSPO-PET study. Neuroimage Clin. 2023;37:103288.","journal-title":"Neuroimage Clin"},{"issue":"7","key":"1518_CR69","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/brain\/awad048","volume":"146","author":"E Aronica","year":"2023","unstructured":"Aronica E, et al. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. Brain. 2023;146(7):2694\u2013710.","journal-title":"Brain"},{"key":"1518_CR70","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nbd.2015.04.016","volume":"80","author":"B Zhang","year":"2015","unstructured":"Zhang B, et al. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex. Neurobiol Dis. 2015;80:70\u20139.","journal-title":"Neurobiol Dis"},{"key":"1518_CR71","doi-asserted-by":"publisher","first-page":"15816","DOI":"10.1038\/ncomms15816","volume":"8","author":"KR Martin","year":"2017","unstructured":"Martin KR, et al. The genomic landscape of tuberous sclerosis complex. Nat Commun. 2017;8:15816.","journal-title":"Nat Commun"},{"key":"1518_CR72","doi-asserted-by":"publisher","first-page":"106282","DOI":"10.1016\/j.eplepsyres.2020.106282","volume":"161","author":"SL Hodges","year":"2020","unstructured":"Hodges SL, Lugo JN. Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy. Epilepsy Res. 2020;161:106282.","journal-title":"Epilepsy Res"},{"issue":"1","key":"1518_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/bpa.12870","volume":"31","author":"CC Hsieh","year":"2021","unstructured":"Hsieh CC, et al. Detection of endophenotypes associated with neuropsychiatric deficiencies in a mouse model of tuberous sclerosis complex using diffusion tensor imaging. Brain Pathol. 2021;31(1):4\u201319.","journal-title":"Brain Pathol"},{"key":"1518_CR74","doi-asserted-by":"publisher","first-page":"106027","DOI":"10.1016\/j.nbd.2023.106027","volume":"178","author":"B Villasana-Salazar","year":"2023","unstructured":"Villasana-Salazar B, Vezzani A. Neuroinflammation microenvironment sharpens seizure circuit. Neurobiol Dis. 2023;178:106027.","journal-title":"Neurobiol Dis"},{"key":"1518_CR75","doi-asserted-by":"publisher","unstructured":"Sanz P, Rubio T, Garcia-Gimeno MA. Neuroinflammation and epilepsy: from pathophysiology to therapies based on repurposing drugs. Int J Mol Sci. 2024 https:\/\/doi.org\/10.3390\/ijms25084161.","DOI":"10.3390\/ijms25084161"},{"issue":"5","key":"1518_CR76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41583-024-00805-1","volume":"25","author":"T Ravizza","year":"2024","unstructured":"Ravizza T, et al. mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment. Nat Rev Neurosci. 2024;25(5):334\u201350.","journal-title":"Nat Rev Neurosci"}],"container-title":["Cell &amp; Bioscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13578-025-01518-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-025-01518-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-025-01518-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:02:42Z","timestamp":1770048162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13578-025-01518-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1186\/s13578-025-01518-3","relation":{},"ISSN":["2045-3701"],"issn-type":[{"value":"2045-3701","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publish the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yijuang Chern holds patents on J4 for the treatment of neurodegenerative diseases.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}